Company: NOTV
Filing Date: 2025-12-05
Form Type: 10-K
Source: 0001628280-25-055483
Chunk: 43

Company: Inotiv, Inc.
Filing Date: 2025-12-05
Form: 10-K
Item: Item 7
Chunk 43
---
 April 4, 2025, a federal judge issued a permanent injunction blocking the implementation of this policy.

With respect to the FDA Modernization Act 2.0, which encourages the industry to explore alternatives to animal testing, many of our acquisitions and investments have been implemented, at least in part, if not sometimes wholly, with the intent to help position us for the future. We believe our future objectives are in line with the goals outlined in the FDA Modernization Act 2.0. Examples of some of our current service offerings which we believe are in line with these goals include predictive computer software, computational toxicology, bioinformatics, proteomics, ex vivo and in vitro cell-based assays, and assays we run in human cells and tissues.

Refer to Part I, Item 1A - Risk Factors of this report for further discussion of potential risks associated with tariffs, client research and development funding levels and the implementation of the FDA Modernization Act 2.0.

Consolidated Overview

Revenue for the fiscal year ended September 30, 2025, increased to $513,024 from $490,739 in the fiscal year ended September 30, 2024, due to a $14,458, or 4.7%, increase in RMS revenue primarily driven by higher NHP product and service revenue and a $7,827, or 4.3%, increase in DSA revenue primarily driven by an increase in safety assessment revenue.

Operating loss for the fiscal year ended September 30, 2025 was $30,902, compared to an operating loss of $86,406 in the fiscal year ended September 30, 2024, a decrease of $55,504, which was primarily driven by the change in RMS operating results for the fiscal year ended September 30, 2025 compared to the fiscal year ended September 30, 2024. For the fiscal year ended September 30, 2025, RMS operating income was $20,611, compared to an operating loss of $31,929 for the fiscal year ended September 30, 2024, a change of $52,540. This change was primarily driven by increased RMS revenue discussed above and a decrease in RMS operating expenses (which include selling, general and administrative and other operating expenses) of $38,187. The decrease in operating expenses was primarily driven by the $28,500 charge incurred during the fiscal year ended September 30, 2024 related to the Resolution Agreement and Plea Agreement, which